MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7454
-0.0446
-5.65%
Pre Market: 0.7800 +0.0346 +4.64% 07:41 01/25 EST
OPEN
0.7880
PREV CLOSE
0.7900
HIGH
0.8000
LOW
0.7250
VOLUME
125.59K
TURNOVER
--
52 WEEK HIGH
1.260
52 WEEK LOW
0.2639
MARKET CAP
69.61M
P/E (TTM)
-1.2362
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Advaxis Says SITC Presentation From Ongoing ADXS-503 Phase 1/2 Clinical Trial Demonstrated Disease Control Rate Of 67%, Overall Response Rate Of 17% In First Six Evaluable Patients With Immediate Prior Progression On KEYTRUDA
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint
Benzinga · 34m ago
Press Release: Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Dow Jones · 42m ago
10-K: ADVAXIS, INC.
Edgar Online - (EDG = 10Q, 10K) · 2d ago
Cancer Immunotherapies Market 2021 Global Industry Analysis by Trends, Size, Share, Company Overview, Growth and Forecast by 2025 Latest Research Report by Market Reports World
Jan 22, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Cancer Immunotherapies Market”...
The Express Wire · 3d ago
Cancer Immunotherapy Market Outlook 2027: Market Trends, Segmentation, consumption by Regional data, Market Growth and Competitive Landscape
AmericaNewsHour · 4d ago
Osteosarcoma Market Report | Major Factors Propelling Growth of Industry Size Valued By CAGR and Revenue Forecast Till 2025
Jan 21, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Osteosarcoma Market” research report...
The Express Wire · 4d ago
Global Prostate Specific Antigen Market Size - Indepth Analysis Report, Industry Growth Factor, Prospect, Overview, Demand, Top Players, and Current Trends with Forecast to 2025
Jan 20, 2021 (The Expresswire) -- Global Prostate Specific Antigen Market report would come handy to understand the competitors in the market and give an...
The Express Wire · 4d ago
Advaxis rallies on first milestone payment under ADXS31-164 licensing agreement
Advaxis ([[ADXS]] +15.2%) received the first milestone payment related to its licensing agreement for ADXS31-164, now known as OST-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.Under
Seekingalpha · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADXS. Analyze the recent business situations of Advaxis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADXS stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 7.34M
% Owned: 7.86%
Shares Outstanding: 93.38M
TypeInstitutionsShares
Increased
6
176.26K
New
12
-98.90K
Decreased
6
280.72K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Independent Director
David Sidransky
President/Chief Executive Officer/Chief Financial Officer/Director
Kenneth Berlin
Non-Executive Vice Chairman/Independent Director
James Patton
Executive Vice President
Andres Gutierrez
Independent Director
Roni Appel
Independent Director
Richard Berman
Independent Director
Samir Khleif
Independent Director
Richard Schwalm
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
More

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.